Stargardt病的视力变化进程
这项回顾性自然史研究纳入327例经基因确诊的Stargardt病1型且至少有2次视力测量的患者,用S形曲线模型分析视力下降的非线性进程。结果显示视力下降速率随疾病阶段和发病年龄不同而变化,视力为0.3 LogMAR时下降最快(0.227 LogMAR/年),早发型和晚发型均较中间型下降更陡(P < .001)。样本量计算显示以视力为主要终点的3年临床试验需139例患者,作者认为视力作为主要终点不切实际。
要点
- 视力下降速率随疾病阶段不同,视力为0.3 LogMAR时下降最快(0.227 LogMAR/年)。
- 早发型(≤10岁)和晚发型(≥45岁)视力下降速率均较中间型(11-44岁)更陡(P < .001)。
- 以视力为主要终点的3年临床试验需139例患者(仅纳入视力0.3 LogMAR者,假设80%治疗效果)。
核心结论
- Stargardt病1型的视力下降呈非线性进程,并因发病年龄不同而异。
- 以视力为终点的临床试验需要较大样本量,使视力成为不切实际的主要终点。
- 本研究生成的模型有助于临床医生为患者提供咨询。
研究设计与样本
- 回顾性自然史研究,纳入327例经基因确诊的Stargardt病1型且至少有2次视力测量的患者。
- 视力用Snellen或早期糖尿病视网膜病变治疗研究(ETDRS)视力表评估并转换为LogMAR进行分析。
- 采用S形曲线模拟视力下降的非线性进程,并按早发型(年龄≤10岁)、中间型(11-44岁)和晚发型(≥45岁)分组比较下降速率。
- 基于结果进行样本量计算,以视力作为主要终点。
主要发现
- 视力下降速率随疾病阶段不同,视力为0.3 LogMAR时下降最快(0.227 LogMAR/年)。
- 非线性模型比较显示,早发型和晚发型组在右眼和左眼的下降速率均较中间型显著更陡(P < .001)。
- 样本量计算显示,仅纳入视力为0.3 LogMAR的患者并假设80%治疗效果时,3年临床试验需要139例患者。
关键数值与推荐
- 视力下降最快时的速率为0.227 LogMAR/年,对应视力为0.3 LogMAR。
- 早发型和晚发型较中间型的视力下降速率更陡,右眼和左眼均P < .001。
- 3年临床试验需139例患者,仅纳入视力0.3 LogMAR者,假设80%治疗效果。
临床怎么用
- 本研究生成的模型有助于临床医生为患者提供咨询。
- 作者认为视力作为主要终点不切实际。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To model the natural history of visual acuity decline in Stargardt disease type 1 using a nonlinear approach, evaluate its variability across different onset groups, and assess the feasibility of using visual acuity as a primary end point in clinical trials. DESIGN: Retrospective natural history study. SUBJECTS: We included 327 patients with a genetically confirmed diagnosis of Stargardt disease type 1 and ≥2 visual acuity measurements over time. METHODS: Visual acuity was assessed using Snellen or Early Treatment of Diabetic Retinopathy Study charts and converted to LogMAR for analysis. The mean visual acuity decline was calculated, and a sigmoid curve was used to model the nonlinear progression of visual acuity decline, resulting in varying rates of decline for early-onset (age ≤10 years), intermediate-onset (11-44 years), and late-onset (≥45 years) groups. Sample size calculations were performed based on the outcomes, using visual acuity as a primary end point. MAIN OUTCOME MEASURES: Visual acuity decline rate. RESULTS: Visual acuity decline rates differed per disease stage, with a highest decline when visual acuity is 0.3 LogMAR (0.227 LogMAR/y). When comparing the nonlinear models, both early-onset and late-onset groups showed a significantly steeper decline rate compared with intermediate onset for both the OD and the OS (P < .001). Sample size calculations showed that 139 patients are needed for a 3-year clinical trial, only including patients with a visual acuity of 0.3 LogMAR and assuming 80% treatment effect. CONCLUSIONS: Visual acuity decline in Stargardt disease type 1 follows a nonlinear course, varying by age of onset. We found that a large sample size is required for visual acuity-based trials, which makes visual acuity an impractical primary end point. However, the generated models in this study will help clinicians in counseling their patients.
引用
- Pas JAAH, Valkenburg D, Li CHZ, et al. The Visual Acuity Course in Stargardt Disease. Am J Ophthalmol. 2025. PMID: 40714056. doi:10.1016/j.ajo.2025.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。